182 related articles for article (PubMed ID: 34094551)
1. Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.
Liu QS; Ass'ad NA; Arana Yi C
Clin Case Rep; 2021 May; 9(5):e03164. PubMed ID: 34094551
[TBL] [Abstract][Full Text] [Related]
2. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Aslan NA; Hıncal HO; Elver Ö; Erol V; Güler N
J Oncol Pharm Pract; 2023 Mar; 29(2):511-516. PubMed ID: 35821583
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.
Moguillansky NI; Fakih HAM; Wingard JR
Respir Med Case Rep; 2017; 21():154-157. PubMed ID: 28560147
[TBL] [Abstract][Full Text] [Related]
4. Bosutinib-induced lung injury: a report of two cases and literature review.
Watanabe N; Takaku T; Tsukune Y; Yasuda H; Ochiai T; Yamada K; Nakazawa H; Hotta S; Nishimaki T; Takagi H; Takahashi K; Komatsu N; Ando M
Int J Hematol; 2022 Jun; 115(6):902-905. PubMed ID: 35229254
[TBL] [Abstract][Full Text] [Related]
5. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.
Seegobin K; Babbar A; Ferreira J; Lyons B; Cury J; Seeram V
Pulm Circ; 2017; 7(4):808-812. PubMed ID: 28914582
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
8. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.
Ault PS; Rose PharmD J; Nodzon PhD LA; Kaled ES
J Adv Pract Oncol; 2016 Mar; 7(2):160-175. PubMed ID: 28090366
[TBL] [Abstract][Full Text] [Related]
10. Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective.
Bauer S; Comer H; Ramsey B; Thomas K
J Adv Pract Oncol; 2021 Jul; 12(5):521-533. PubMed ID: 34430062
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
14. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
16. A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report.
Aria AB; Chen L; Huen AO
SAGE Open Med Case Rep; 2018; 6():2050313X18795075. PubMed ID: 30214807
[TBL] [Abstract][Full Text] [Related]
17. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Shen AQ; Wilson NM; Gleason SL; Khoury HJ
Ther Adv Hematol; 2014 Feb; 5(1):13-7. PubMed ID: 24490020
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
Yüzbaşıoğlu MB; Eşkazan AE
Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
[No Abstract] [Full Text] [Related]
19. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
[TBL] [Abstract][Full Text] [Related]
20. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
